Compare BAK & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | ALVO |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | Brazil | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2002 | N/A |
| Metric | BAK | ALVO |
|---|---|---|
| Price | $2.45 | $3.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.40 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.1M | 638.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.02 | $13.28 |
| Revenue Next Year | $7.04 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $2.94 |
| 52 Week High | $5.40 | $9.94 |
| Indicator | BAK | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 35.84 |
| Support Level | $2.32 | $2.99 |
| Resistance Level | $2.78 | $3.94 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 40.20 | 0.98 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.